Amgen comes in second with its latest batch of KRAS data, but its rival is still having problems catching up

Amgen once again finds itself touting KRAS G12C data that don’t measure up to a rival at Mirati, as the smaller player struggles to play catch-up. After the market closed on Monday, the pharma giant posted a set of new data from their Lumakras (sotorasib) team, spotlighting a 21% objective…